LLY

1,019.16

+2.69%↑

JNJ

210.09

+2.68%↑

ABBV

222.92

-0.29%↓

UNH

339.07

+4.39%↑

AZN

90.72

+0.2%↑

LLY

1,019.16

+2.69%↑

JNJ

210.09

+2.68%↑

ABBV

222.92

-0.29%↓

UNH

339.07

+4.39%↑

AZN

90.72

+0.2%↑

LLY

1,019.16

+2.69%↑

JNJ

210.09

+2.68%↑

ABBV

222.92

-0.29%↓

UNH

339.07

+4.39%↑

AZN

90.72

+0.2%↑

LLY

1,019.16

+2.69%↑

JNJ

210.09

+2.68%↑

ABBV

222.92

-0.29%↓

UNH

339.07

+4.39%↑

AZN

90.72

+0.2%↑

LLY

1,019.16

+2.69%↑

JNJ

210.09

+2.68%↑

ABBV

222.92

-0.29%↓

UNH

339.07

+4.39%↑

AZN

90.72

+0.2%↑

Search

Simulations Plus Inc

Atvērts

SektorsVeselības aprūpe

19.78 1.8

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

19.36

Max

20

Galvenie mērījumi

By Trading Economics

Ienākumi

67M

-681K

Pārdošana

-2.9M

17M

P/E

Sektora vidējais

48.528

77.671

EPS

-0.034

Dividenžu ienesīgums

0.48

Peļņas marža

-3.9

Darbinieki

212

EBITDA

327K

5.3M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+4.59% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.48%

2.35%

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

49M

394M

Iepriekšējā atvēršanas cena

17.98

Iepriekšējā slēgšanas cena

19.78

Ziņu noskaņojums

By Acuity

50%

50%

195 / 374 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 10. dec. 22:02 UTC

Peļņas

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

2025. g. 10. dec. 21:46 UTC

Peļņas

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

2025. g. 10. dec. 23:52 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

2025. g. 10. dec. 23:43 UTC

Tirgus saruna

Nikkei May Rise After Fed Rate Cut -- Market Talk

2025. g. 10. dec. 23:36 UTC

Tirgus saruna

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

2025. g. 10. dec. 23:20 UTC

Peļņas

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

2025. g. 10. dec. 23:15 UTC

Peļņas

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

2025. g. 10. dec. 22:59 UTC

Tirgus saruna
Peļņas
Iegādes, apvienošanās, pārņemšana

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

2025. g. 10. dec. 22:45 UTC

Tirgus saruna

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

2025. g. 10. dec. 22:40 UTC

Peļņas

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

2025. g. 10. dec. 22:06 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

2025. g. 10. dec. 22:06 UTC

Peļņas

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

2025. g. 10. dec. 22:02 UTC

Peļņas

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

2025. g. 10. dec. 22:00 UTC

Peļņas

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

2025. g. 10. dec. 21:53 UTC

Peļņas

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

2025. g. 10. dec. 21:50 UTC

Iegādes, apvienošanās, pārņemšana

Investors Bet That a Higher Bid for Warner Is Coming -- Update

2025. g. 10. dec. 21:50 UTC

Tirgus saruna
Peļņas
Iegādes, apvienošanās, pārņemšana

Financial Services Roundup: Market Talk

2025. g. 10. dec. 21:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2025. g. 10. dec. 21:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2025. g. 10. dec. 21:45 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

2025. g. 10. dec. 21:33 UTC

Peļņas

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

2025. g. 10. dec. 21:32 UTC

Peļņas

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

2025. g. 10. dec. 21:28 UTC

Iegādes, apvienošanās, pārņemšana

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

2025. g. 10. dec. 21:25 UTC

Peļņas

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

2025. g. 10. dec. 21:18 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

2025. g. 10. dec. 21:16 UTC

Peļņas

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

2025. g. 10. dec. 21:15 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

2025. g. 10. dec. 21:15 UTC

Peļņas

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

2025. g. 10. dec. 21:14 UTC

Peļņas

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

2025. g. 10. dec. 21:14 UTC

Peļņas

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

4.59% augšup

Prognoze 12 mēnešiem

Vidējais 20.5 USD  4.59%

Augstākais 25 USD

Zemākais 16 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

5 ratings

3

Pirkt

2

Turēt

0

Pārdot

Noskaņojums

By Acuity

195 / 374 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat